ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Industrials / DHR
DE (70) TMO (73) JCI (69) NOC (67) ⌘ Pro Terminal →

Danaher Corporation (DHR) — RQD Stock Rating Cockpit

$227.97 -1.83% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $226.79

Danaher Corporation (DHR) carries a Roarable Rating of C+ (Hold) with 69/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C+ • HOLD / WATCH Cap $163.38B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on DHR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is DHR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Danaher Corporation (NYSE: DHR) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 69/100 at a spot price of $227.97 (-1.83% 1D, market cap $163.38B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 18/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 11/20. Across 486 tracked Industrials issuers, DHR ranks #42 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does DHR compare to DE and TMO in the Industrials sector?
▼

Within the Industrials sector (Industrial Machinery/Components), DHR carries a Roarable C+ (69/100 RQD), trailing P/E of 46.1x, gross margin of 59.1%, and ROIC of 6.1%. By comparison, DE (Deere & Company) holds a B- grade (70/100 RQD, P/E 35.4x, ROIC 9.3%, cap $182.13B) and TMO (Thermo Fisher Scientific Inc) posts a B grade (73/100 RQD, P/E 39.0x, ROIC 9.3%, cap $257.71B). Among the 5-stock peer group, NOC leads on earnings multiple (19.1x) while JCI leads on capital efficiency (15.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for DHR?
▼

Per DHR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000313616), Danaher Corporation generated $24.57B in revenue (+2.9% YoY), $3.61B in net income, and $5.26B in free cash flow against $83.46B in total assets and $18.42B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Priced at 46x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $226.78 (-0.52%)🧬 Cannibal Buyback (-0.96% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 21.4% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 69/100 (C+) historically posted market-perform odds over rolling 90-day windows (+2.0% avg 90D alpha vs SPY • 57.3% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C+
025507510069
2-of-3 Quant Analysts Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw B- · Rk C+
Cash (13)Whales (18)SEC (14)Macro (13)CEO (11)
Each axis scored 0–20
12M PRICE TARGET CONE+4.9% Base Target
$282 Bull$239 Base$187 Bear
📬 FREE DHR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DHR)Realized 20D OHLCV Swing Band: ±5.7%
Deterministic 5-Pillar Attribution (69/100 Composite)
🔍 WHY DHR SCORES 69/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+18/20 pts (26% of score)

20D Institutional Volume Accumulation (±5.7% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (20% of score)

Altman Z-Score 3.85 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution11/20 pts (-9 pt drag)

Cannibal Buyback (-0.96% YoY Shares) & executive Form 4 sales trim 9 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
61
Grade C$224.69+4.1% Next Q
Q2 (-2Q)
64
Grade C+$233.86+0.1% Next Q
Q3 (-1Q)
66
Grade B-$234.07-2.6% Next Q
Current
69
Grade C+$227.97+2% Hist 90D α
Trajectory: C (61) → C+ (69)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the DHR Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 69/100 (C+) score, DHR faces multiple-compression risk if 46.1x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 46x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-0.96% YoY Shares) — any gross margin slip below 56.6% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($219.98) or 200D SMA ($201.09) invalidates the momentum regime and cuts Target Base ($239.25) toward Bear Floor ($186.62).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DHR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “DHR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 69%NO 31%Trade / Inspect Odds →
RSI-14 MOMENTUMBULLISH MOMENTUM
55.830 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.85>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE82% OF RANGE
L: $161$227.97H: $243
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (59.1% gross margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: CRQD 13 / 20
2. Big Money & Insiders● BUYING
Are whales & executives buying or selling?

Hedge funds and options traders are leaning bullish, showing strong institutional appetite.

Factor Grade: BRQD 29 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: C+RQD 27 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

2-of-3 Quant Analysts Bullish on DHR

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
NEUTRAL (65)

6.1% ROIC with 59.1% gross margin and 3.15% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (70)

Altman-Z 3.85 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BULLISH (70)

29/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like DHR
  • ✓Big institutional funds and options desks are actively positioning on the bullish side.
Bear Case: What Could Go Wrong
  • !Priced at 46x earnings—high expectations leave less room for a lukewarm quarter.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (DHR Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
DHR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +30.99%▲ ASCENDING CHANNEL
2026-11-03O $237.0H $237.0L $228.0C $228.0VOL 3.76M
RES: $239.5SUP: $174.0SMA50: $220.0SMA200: $201.1
$243.9$221.4$198.9$176.4$154.0RES $239.5SUP $174.0$228.02026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DHR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DHR Butterfly Map → + Track DHR →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
34.2%/yr Implied 5Y Growth

vs. +2.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on DHR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →
DHR → NVO Analyst Hypothesis
Novo Nordisk $6B+ annual API manufacturing expansions utilize downstream purification chromatography resins and single-use filtration consumables where Danaher Cytiva and Pall hold leading bioprocess share.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for DHR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DHR)

Industrials Rank #42 of 486 ⚔️ DE vs DHR Full Matrix →

1. Head-to-Head Industrials Peer Comparison (DHR vs. DE, TMO, JCI, NOC)

Industry: Industrial Machinery/Components (208 Tracked Issuers)

Across 486 tracked Industrials securities in the Roarable RQD universe, Danaher Corporation (DHR) ranks #42 by composite RQD confidence (69/100, grade C+) and #6 by equity capitalization ($163.38B). Within this direct 5-issuer industry benchmark cohort, NOC leads on earnings valuation at 19.1x trailing P/E, while JCI leads on capital efficiency and profitability with 15.6% ROIC and 36.4% gross margin. TMO currently holds the highest overall quantitative score in the immediate peer group at 73/100 (B) compared with DHR at 69/100 (C+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
DHR ACTIVE
Danaher Corporation
C+ 69/100 46.1x 59.1% 6.1% -1.83% $163.38B Benchmark Subject
DE
Deere & Company
B- 70/100 35.4x — 9.3% -1.17% $182.13B /de-vs-dhr →
TMO
Thermo Fisher Scientific Inc
B 73/100 39.0x — 9.3% -2.06% $257.71B /tmo-vs-dhr →
JCI
Johnson Controls International plc Ordinary Share
C+ 69/100 29.1x 36.4% 15.6% -1.70% $90.27B /jci-vs-dhr →
NOC
Northrop Grumman Corporation
C+ 67/100 19.1x — 13.0% -0.40% $79.21B /noc-vs-dhr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000313616 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Danaher Corporation (DHR) reported GAAP revenue of $24.57B (+2.9% vs. FY2024 revenue of $23.88B , and +2.8% cumulative change since FY2023) , GAAP net income of $3.61B, operating cash flow of $6.42B, and free cash flow of $5.26B (-0.7% YoY). On the balance sheet, DHR closed FY2025 with $83.46B in total assets against $18.42B in total debt (Altman Z-Score: 3.85, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $24.57B $3.61B $6.42B $5.26B $83.46B $18.42B
FY2024 (FY) 2024-12-31 $23.88B $3.90B $6.69B $5.30B $77.54B $15.50B
FY2023 (FY) 2023-12-31 $23.89B $4.76B $7.16B $6.09B $91.70B $21.46B

3. DHR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DHR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Danaher Corporation (NYSE: DHR) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 69/100 at a spot price of $227.97 (-1.83% 1D, market cap $163.38B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 18/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 11/20. Across 486 tracked Industrials issuers, DHR ranks #42 in composite RQD confidence.

How does DHR compare to DE and TMO in the Industrials sector?

Within the Industrials sector (Industrial Machinery/Components), DHR carries a Roarable C+ (69/100 RQD), trailing P/E of 46.1x, gross margin of 59.1%, and ROIC of 6.1%. By comparison, DE (Deere & Company) holds a B- grade (70/100 RQD, P/E 35.4x, ROIC 9.3%, cap $182.13B) and TMO (Thermo Fisher Scientific Inc) posts a B grade (73/100 RQD, P/E 39.0x, ROIC 9.3%, cap $257.71B). Among the 5-stock peer group, NOC leads on earnings multiple (19.1x) while JCI leads on capital efficiency (15.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for DHR?

Per DHR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000313616), Danaher Corporation generated $24.57B in revenue (+2.9% YoY), $3.61B in net income, and $5.26B in free cash flow against $83.46B in total assets and $18.42B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Priced at 46x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.

Where is DHR trading relative to its 50-day, 200-day, and 52-week technical levels?

DHR last traded at $227.97 (-1.83% on volume of 3,162,026 shares), positioning the stock +3.63% above its 50-day simple moving average ($219.98) and +13.37% above its 200-day simple moving average ($201.09). Across its 52-week range of $160.93 to $242.80, DHR sits at the 81.9% percentile with a 14-day RSI of 55.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.7% ($214.98 to $240.96).

Direct Sub-Reports: DHR RQD Cockpit DHR 12M Forecast DHR Earnings & Move DHR Dividends & DRIP DHR Insiders & 13F DHR Whale Options DHR Profit Sankey DHR News & Why
ROARABLE RATING BRIEF • RQD 69/100 (C+) ✓ SEC XBRL & RQD VERIFIED

DHR — Danaher Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Danaher Corporation (DHR) earns a live Roarable RQD composite score of 69/100, corresponding to a C+ letter grade (Roarable Hold) at a spot price of $227.97 (-1.83% 1D, market capitalization $163.38B).

  • Fundamental Cash Engine (13/20): Anchored by return on invested capital (ROIC) of 6.1%, gross margin of 59.1%, operating margin of 19.1%, and free cash flow yield of 3.15%.
  • Whale 13F & Options Flow (18/20) + Insider Conviction (11/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (13/20) + Forensic Balance Sheet (14/20): Incorporates a 0.90x equity beta, Altman Z-Score of 3.85, Piotroski F-Score of 7/9, and Debt/Equity of 0.35x.

2. Business Model, Unit Margins & SEC Financial Trajectory

. The Biotechnology Segment's bioprocessing business is referenced as a supplier of chromatography resins and single-use filtration consumables. — for the detailed product lines, customer base beyond the referenced Novo Nordisk relationship, or revenue mix by segment.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Danaher Corporation (DHR) reported $24.57B in annual revenue (up from $23.88B in FY2024, +2.9% YoY) and $3.61B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($23.89B revenue, $4.76B net income) through FY2025, DHR scaled operating cash flow to $6.42B and free cash flow to $5.26B, backed by $83.46B in total assets against $18.42B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C+ • RQD 69/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of 3.15% and institutional whale pillar of 18/20. With Fundamental Cash Engine at 13/20 and Institutional Whale Flow at 18/20, sustained execution supports upside toward the upper end of the $160.93 – $242.80 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Priced at 46x earnings—high expectations leave less room for a lukewarm quarter. Investors must weigh 46.1x trailing P/E and 30.9x EV/EBITDA against 19.1% operating margins and a 0.90x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The analyst hypothesis posits that Novo Nordisk's API manufacturing expansions use downstream purification chromatography resins and single-use filtration consumables in which Danaher's Cytiva and Pall businesses hold leading bioprocess share. Upstream and downstream dependencies run from DHR's bioprocessing consumables to NVO's GLP-1 API production. The graph flags a capacity or margin constraint: broader bioprocessing equipment CapEx softness among smaller clinical biotechs could mask recurring GLP-1 consumables strength. A competing explanation is a shift from recombinant yeast fermentation toward synthetic solid-phase peptide synthesis or oral small molecules, which would alter purification resin intensity per kilogram of API. Investors should watch the bioprocessing order book-to-bill print and any change in GLP-1 manufacturing modality.

  • Key Question #1: Can DHR sustain or expand its 19.1% operating margin and 6.1% ROIC against Industrial Machinery/Components peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $24.57B and free cash flow of $5.26B, how will capital allocation balance growth reinvestment against $18.42B in total debt?
  • Key Question #3: How sensitive is DHR's 42.9x forward P/E multiple to Industrials capital spending cycles and macro interest-rate shifts (Beta 0.90x)?

DHR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Danaher Corporation (DHR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to DHR Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

DHR Bull vs. Bear Conversation Board — What's Your Call at $227.97?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON DHR 🐻 33% BEARISH CONVICTION
1. Pick Your Side on DHR:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $294.93 (+27.0%)
📌 Pinned Debate

Institutional whale flow scores 19/20 in the Roarable RQD rating, the strongest pillar in the sources.

Institutional whale flow scores 19/20 in the Roarable RQD rating, the strongest pillar in the sources.. When you look under the hood at DHR, Fundamental Cash Engine is 13/20 with 59.1% gross margins and 6.1% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (18/20) has been quietly accumulating below $242.80. My 12M target is $294.93.

SectorRotator 🐂 BULL

@FadeTheHype Fair point on 46.1x trailing P/E, but you're ignoring the forward operating leverage in Industrial Machinery/Components. If gross margin (59.1%) holds, EPS grows into the multiple faster than bears think.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $190.43 (-18.0%)
Spot @ $232.23

P/E (TTM) of 46.1 with ROIC at 6.1% and net income falling from $4.76B to $3.61B leaves little cushion if earnings disappoint.

Fading this rally in DHR at $232.23. P/E (TTM) of 46.1 with ROIC at 6.1% and net income falling from $4.76B to $3.61B leaves little cushion if earnings disappoint.. With a beta of 0.9 and the stock sitting at $232.23 (52-wk range $160.93–$242.80), the easy multiple expansion is already priced in.

LIVE TAPE